Why Recursion Pharmaceuticals, Inc. (RXRX) Stock Fell 6.4% on Nov 17, 2026
as of Tuesday, 4:25 PM ET
The reason we found
JPMorgan cuts Recursion price target to $7
JPMorgan kept an Overweight rating but reduced its price target from $10 to $7, signaling lower expectations for Recursion’s valuation. That downgrade in the target can pressure shares, although the unchanged positive rating makes it a partial rather than definitive explanation for the 6.37% decline.
analyst price target cutmedium confidence
Sources 1
Our call
Buy moredated Oct 15, 2026
Recursion Pharmaceuticals fell 23% over the past five trading days, far more than other biotech stocks (down 4.4%), but its sales grew 56% over the past year. We'd stop buying if Recursion Pharmaceuticals' next report shows sales growth below 28% or misses profit forecasts.
Other moves on Nov 17
- SLS+156.8%SELLAS surges after leukemia vaccine succeeds in Phase 3 trial
- SPCE−17.3%Virgin Galactic Slides After Analysts Cut Price Targets
- ACM+11.1%AECOM jumps on earnings beat and stronger 2027 outlook
- CRM−9.4%Salesforce Slides on Engineering Chief Departure and AI Fears
- MNSO+8.3%MINISO reports strong nine-month revenue growth despite Q3 misses
- ENPH−7.5%Evercore cuts Enphase price target to $30